Diagnosis | Follow-up | Follow-up | |||
---|---|---|---|---|---|
PC surface aberrant markers (SAM) | SAM expression (% of patients) | MRD-negative by cy-Ig light chains ratio on SAM percentage above the normal threshold 6, 7 (Putative surface MRD-positive) (% of samples) | MRD-positive by cy-Ig light chains ratio on SAM percentage below the normal threshold 6, 7 (Putative surface MRD-negative) (% of samples) | ||
CD19neg | 98 % | CD19neg ≥30 % | 2.5 % | CD19neg <30 % | 26 % |
CD45weak/neg | 63 % | CD45weak/neg ≥6 % | 38 % | CD45weak/neg <6 % | 39 % |
CD56pos | 74 % | CD56pos ≥15 % | 15 % | CD56pos <15 % | 27 % |
CD117pos | 41 % | CD117pos ≥1 % | 0 % | CD117pos <1 % | na |
CD33pos | 26 % | CD33pos ≥6 % | 60 % | CD33pos <6 % | 0 % |